Yes. Hello everybody, welcome to the presentation of annual result. I will start with a quick reminder of AEVIS Value. We are investing for a better life. We invest in service to people. We try to create value, grow, and manage company for the long term. We try to bond partnership with entrepreneur and founder in the company that we're investing in. Our focus sector, healthcare, hospitality, lifestyle, and infrastructure. As you know, we have Swiss Medical Network, Nescens, and Swiss Ambulance Rescue in our healthcare investment. We just divested Medgate in March. In hospitality and lifestyle, we have the Victoria-Jungfrau Group with 9 hotels in Switzerland and in London. The Victoria-Jungfrau in Interlaken, Bellevue Palace, Crans Ambassador, La Réserve Eden au Lac in Zurich, Hotel Monte Rosa, Hotel Mont Cervin and Schweizerhof in Zermatt, the AlpenGold Hotel in Davos, and L'oscar in London.
We also have an investment for 27% in Batmaid Group, which is a platform for home service delivery. On the infrastructure side, we have Swiss Hotel Properties, a company dedicated to hotel building, and Infracore, a company dedicated to healthcare buildings. Our investment activity in 2021 and 2022. We divested 10% of Swiss Medical Network in March 2021 to Medical Properties Trust. We sold 60% of Swiss Ambulance Rescue to Touring Club Suisse in February 2021. We invest up to 27% in Batmaid in September 2021. In 2022, subsequent event is the sale of our participation in Medgate to Otto Group in March 2022. If I go in detail in all those transactions. We've sold 10% of the share capital of Swiss Medical Network to Medical Properties Trust. The transaction was based on an enterprise value of CHF 1.7 billion for 100% of Swiss Medical Network.
For AEVIS, this transaction led to a cash inflow of CHF 145 million and increasing equity by CHF 98 million because the book value of Swiss Medical Network is CHF 20 million. The transaction was in March 2021. What is the rationale? It's unlocking a substantial value creation. It's also a sign to open the shareholder base to strategic investor. We are discussing with several strategic partner who can invest in Swiss Medical Network and help Swiss Medical Network to become the integrated care provider. The sale of 60% in Swiss Ambulance Rescue. The idea was to have a Swiss institutional partner to develop this rescue network within Switzerland. We sold 60% to TCS. Touring Club Suisse is a very well-known organization with more than 1.5 million members.
Since we did that in 2021, we already acquired two additional rescue companies, TCS Swiss Ambulance Rescue became the biggest rescue organization in Switzerland. We are now the largest private ambulance service provider in Switzerland. The acquisition of a minority stake in Bat Group We have signed an investment agreement to take up to 27% in Batmaid. The investment will be up to CHF 25 million, based on CHF 75 million pre-money value, and it's structured in various installments that can lead to this 27%. Bat Group is the parent company of Batmaid, which is the leading on-demand home cleaning platform in Switzerland. We are helping Bat Group to become more than a cleaning company, but a company that brings hospitality into private homes.
There is a clear strategic fit with our strategy because we also think that we can use the same platform, Batmaid, to manage the home care delivery in the healthcare activity. The sale of 40% in Medgate. In 2016, we acquired 40% in Medgate, and we helped the company to become the leader in telemedicine in Switzerland. Medgate wanted to make an expansion international. We do not want to invest internationally in healthcare because healthcare is highly political, and you have to understand and to be connected to the system. Medgate has completed the financing round, and during this financing round, we've sold our 40% interest to Otto Group. The transaction was in March 2022, and the exit generated a cash proceed of CHF 66 million and a CHF 47 million capital gain. In Swiss Medical Network, there was some investment activity also.
Swiss Medical Network took over 100% of Klinik Pyramide am See, 100% of Rosenklinik, 52% of Hôpital du Jura Bernois, and we also bought 80% of Xundheitszentrum from the Erste Klasse, and Erste Klasse is retaining 20% in Xundheitszentrum. What's the detail of those transactions? In 2011, we acquired a 20% share in Klinik Pyramide. We have been working with Pyramide since then, and in July 2021, we acquired the remaining 80%. The idea is to consolidate the Zurich market, and we expect to have a lot of synergy with Bethanien in Zurich. The increase of the participation in Rosenklinik. We did the 40% investment in 2019, and we had the option to take 100% of the company, and together with the founders, the seller, we reached an agreement to fully integrate the Rosenklinik. That's a clinic in the Zurich area, but on the canton of St. Gallen.
Hôpital du Jura Bernois, we will explain in more detail what is our project in Arc Jurassien. We had this option to acquire an additional 17% in HJB. We exercised this option in August 2021. Hôpital du Jura Bernois is now fully consolidated in Swiss Medical Network since September. The Xundheitszentrum, that was 11 doctor's office medical centers across Switzerland from Erste Klasse. We took over this, and we are managing these 11 centers and integrating this center into the Swiss Medical Network in each region. In the hospitality and infrastructure, we also made an investment. In March 2022, Swiss Hotel Properties acquired the building of L'oscar London. It's a freehold building located in Holborn, and Victoria-Jungfrau acquired the operating company of L'oscar London. L'oscar is now managed with our other hotel within Victoria-Jungfrau.
The transaction, it's a hotel of 39 rooms and suites in central London. We also acquired the adjacent building, which gives us the ability to expand the hotel with 10 additional rooms and probably a spa and some amenities for the hotel. The price of this transaction was GBP 60 million, and we think that's very important for our hospitality activity to expand abroad, to be able also to retain talent, and make our staff have some work experience abroad, and London is the ideal start for this international expansion. Let's go to the financial of AEVIS. I will start with the statutory AEVIS figure. That's reflecting the investment activity. The income in 2021 was CHF 216 million, and we made a net profit of CHF 197 million at the holding level.
We also increased the equity from CHF 426 million- CHF 639 million, and we also reduced the liability with the repayment of CHF 150 million bonds in June 2021. We create value. We have been creating value since 2012. We can see that the equity has strongly increased in these almost ten years, and that the share price is following also this value creation in the equity. The consolidated P&L, we achieve CHF 895 million revenue, CHF 787 million net revenue.
It is a 22.8% growth, with 9.8% organic growth, which is the result of the development CapEx we invest in 2019 and 2020. EBITDA is CHF 152 million. EBITDA, CHF 78 million. The rental expense is increased by some CHF 11 million because last year in 2020, we had a rent holiday due to the COVID situation. EBITDA, CHF 78 million and EBIT of CHF 16.7 million. The balance sheet, we have increased total assets to CHF 1.7 billion.
The accounts receivable are mostly insurance and cantons, so it is 100% guarantee. It is almost cash-like. Financial liabilities are stable, and we also increased the equity in the consolidated account from CHF 490 million- CHF 585 million. Improving the equity ratio and improving also the leverage ratio of AEVIS on a consolidated basis. That is the consolidated segment reporting. Hospitals have achieved very good results with 23% EBITDA. Hospitality has a net revenue of CHF 114 million. Within this CHF 114 million, there is, of course, the one-off payment from cantons and confederation, the Härtefallhilfe, the Kurzarbeit, for some CHF 30 million. The real estate also improved its result. There was no rent holiday in 2021. That is the segment reporting. The capital market. We have now a market capitalization of CHF 1.6 billion.
Current stock price is CHF 18.95, which is, in our view, not the sum of the parts, so it is still below the sum of the parts price when you look at our investment. We also show on this slide the total shareholder return that we did since 2018, with the exception of 2020, of course, with the COVID. Healthcare Swiss Medical Network. We have 22 hospitals, around 40 medical centers, 2,300 physicians. We have been creating value through acquisitions since 2002. We expect to have more than CHF 750 million revenue in 2022. We have seven clusters for Swiss Medical Network. We divided Switzerland in regions. Geneva, Vaud, the Aargau, Fribourg, Valais, Mittelland, region Zurich, and region Ticino. The vision for Swiss Medical Network is to create a pioneer in integrated care.
We want to get rid of this vicious triangle where the ideal patient for insurance state is a dead patient, and the ideal patient for us, so doctor, hospital, pharma, is a chronic patient. To try to align the interests of insurance and provider, we aim to create the first payvider in Switzerland, which will include insurance, health plan, education, and research. The idea is to have an offer for the member for its whole life path from birth to death. Maybe a focus on Arc Jurassien. The Hôpital du Jura Bernois, and what we have in Canton Neuchâtel. We have one region with a health center hospital, a mental hospital, radiology center, elderly care home, rescue service, laboratory, and pharmacy. We also have partnership with Centre hospitalier Bienne, Inselspital in Bern, and the Inselspital Basel.
We have a partnership with rehabilitation and home care delivery. In this region, there is a population of 250,000 people, with quite good distribution between active population and retired population. In this region, we have 600 doctors, and we are doing 21,000 cases per year. We are now a partner with Canton of Bern in Hôpital du Jura Bernois. The idea is to change the name of this company into Réseau de l'Arc, to make this company a real accountable care organization, a real payvider. We will have as additional partner an insurance company. That means an insurance company is going to invest in the Réseau de l'Arc to be shareholder in the Réseau de l'Arc and make a tailor-made health plan for the member who want to be followed and treated by the Réseau de l'Arc.
TCS Swiss Ambulance Rescue, we have now 40% in this company. It is now the biggest rescue organization in Switzerland since we acquired 2 additional company, with a presence in Canton of Vaud, Geneva, Zug, and Aargau via Zurich. We plan to pursue this buildup together with the Touring Club Suisse. We have a very strong motivation from our partner, TCS, to build this network. In hospitality and lifestyle, Victoria-Jungfrau with these 9 hotels in Switzerland and the U.K. It is a total of 941 room and 183,000 overnight stay in 2021. 2021 is still not a normal year. 2021 was heavily affected in the first half by the COVID. Number of employees not accurate. We have around 1,000 employee in the hospitality segment, and our average room rate is CHF 423 for 2021. That is the current hotel portfolio with a very strong presence in Zermatt.
We are the largest hotelier in Zermatt. This destination has made extraordinary winter season this year. We are also a big player in Interlaken with the Victoria-Jungfrau Collection. We have this cooperation with the Michel Reybier Hospitality for the hotel organization. The management of Victoria-Jungfrau and Michel Reybier Hospitality is done together, with eight owned hotel and two affiliated hotel in Switzerland, one owned hotel in U.K. and five affiliated hotel in France. Bat Group, which is Batmaid, Batsoft, and Batwork, was founded in 2014. It is an on-demand platform for B2C and B2B cleaning services. Batmaid has around 20,000 active clients and 1,800 Batmaid. You can add to this Putzfrau.ch, because Putzfrau.ch has been acquired by Bat Group The integration process is scheduled to be in 2023. Putzfrau.ch has almost the same size in the Swiss German part. We have now eight active country within Batmaid.
Real estate and infrastructure at 30% shareholding in Infracore. We have 50% of the voting rights. The market value of the portfolio is CHF 1.2 billion. We will pay CHF 36.5 million dividend for 2021. This will be paid in 2022. AEVIS will receive 30% of this CHF 36.5 million. That is the portfolio of Infracore. Within Switzerland, Swiss H otel Properties has a market value of CHF 530 million. 18 properties. We had a CHF 29.9 million net income, and a total of 100,000 sq m. That is the hotel portfolio of Swiss Hotel Properties with hotel in Switzerland and in London. This is the portfolio detail. You can see that in Zermatt, we have a very important presence with these three hotels and a lot of commercial properties which are rented to third-party tenants, among them Migros.
For instance, we have Migros as a tenant in Zermatt for the Migros, the Interhome, and for the restaurant Molino. L'oscar is the only foreign property. Outlook. COVID-19, I think, is now behind us. The last measure are now falling on Friday. We think that COVID is behind us, but there's still uncertainty with the war in Ukraine. We have no big exposure to Russian markets. Russian market in hospitality was CHF 2.5 million per year, and in hospital, in healthcare, total revenue of Ukraine and Russia was around CHF 12 million. Not a big share, but still, this war is something that is of concern and we are closely monitoring this evolution.
We have already at the holding level, a promising start because of the sale of the 40% of Medgate and also the dividend that will be paid by Swiss Medical Network, Infracore, and Swiss Hotel Properties. We will continue to pursue our support to Swiss Medical Network for 2022. We also will support Victoria-Jungfrau and the Swiss Hotel Properties for the growth. We will continue to monitor the market and acquire the best landmark building that we can find. I'm finished with my presentation, and I will hand over to the operator for the question and answer session.
Our first question today comes from Christian Affolter of AGC. Please go ahead. Your line is open.
Yes, hello. Just a question on this Medgate divestment and the division of integrated care. Would Medgate have played a role in the integrated care vision? Or is it anyway separate from the project you have in the Jura Bernois and Neuchâtel?
When we acquired Medgate back in 2016, we agreed that Medgate will stay a neutral gatekeeper for the insurance. That means that we never used Medgate to funnel patients to our hospital. Our hospital and our doctor were Medgate partner, but at the same level as the other partners. Medgate was a neutral organization, and the business model of Medgate is to contract with insurance and to help insurance to reduce the cost. That was not intended to integrate more Medgate. Of course, we are going to develop our own telemedicine service within Switzerland. Starting with this Arc Jurassien, telemedicine is a key part of the integrated care, it's more a B2C telemedicine. That means that, of course, there will be a dedicated service for Swiss Medical Network.
Thank you very much.
Thank you. Once again, as a reminder, that is star one if you would like to ask a question today. We will pause for a further moment. There appears to be no further questions at this time. Okay, apologies. We're just receiving a follow-up question from Christian. Please go ahead. Your line is open.
Perhaps just on this, you said that you are closely monitoring the evolution regarding Russia and Ukraine. What does that mean on behalf of your activities? Are you maintaining activities at the moment or what's your approach?
Yeah, of course, in the hospital and same in the hotels, the people that come in Switzerland are allowed to travel so they are not people under sanction. Especially in the hospital, our philosophy is to treat all the patients disregarding their origin or religion or country. Of course, probably some of our patients will not be able to access Switzerland because of the sanction. There will be an effect. On our side, we are treating all the patients disregarding their origin.
Okay. Thank you.
If there are no further questions today, that will conclude today's call. Thank you for your participation, ladies and gentlemen. You may now disconnect.